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Abstract
Introduction: There is a dearth of evidence about the effects 
of Sonas, a multisensory stimulation on people with demen-
tia (PWD). The main aim of this study was to examine the ef-
fects of the Sonas program on anxiety and depression in 
nursing home (NH) residents with dementia. Methods: In all, 
120 PWD ≥65 years of age from 6 NHs were included in a 
randomized control trial and were allocated to 1 of 3 groups 
for 24 weeks: a Sonas program group (n = 48), a reading 
group (n = 32), and a control group (n = 40). One hundred 
and five participants completed follow-up assessments. 
Anxiety and depression were assessed by the Rating Anxiety 
in Dementia (RAID) scale and the Cornell Scale for Depres-
sion in Dementia (CSDD), respectively. Generalized linear 
mixed models were estimated to assess trends in the propor-
tion of participants with anxiety (a RAID score ≥11) and de-
pression (a CSDD score ≥10). Results: No significant reduc-
tion in anxiety from baseline to follow-up was observed in 
any of the groups. Participants in the Sonas group showed a 
significant reduction in depression from baseline to 12 
weeks (p = 0.001) and from baseline to 24 weeks (p = 0.009). 
Conclusion: The Sonas program had no effect on severity of 
anxiety but a reduction in depressive symptoms was found 
in PWD. © 2021 The Author(s)
Published by S. Karger AG, Basel
Introduction
Anxiety and depression as symptoms at disease level 
are common conditions (comorbidities) in older people 
with dementia (PWD) and are more frequent in PWD 
living in nursing homes (NHs) than in those living at 
home [1–5]. Some studies report that anxiety and depres-
sion are more prevalent in early than in late stages of de-
mentia [6, 7], but other studies report that anxiety and 
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depression are equally prevalent in all stages of dementia 
but may be diagnosed as challenging behavior (especially 
as agitation) in the late stages [8–11]. Anxiety and depres-
sion can be difficult to diagnose in the late stages of de-
mentia as patients may have difficulties in expressing 
their feelings verbally and also due to the overlapping 
symptoms of dementia, depression, and physical morbid-
ities in older people [12–14]. Regardless, anxiety and/or 
depression can have many negative effects on PWD, their 
family, and professional caregivers, and thus needs to be 
diagnosed and treated [2, 15–17].
The interplay of biological and psychosocial factors 
could be the underlying causes of anxiety and depression 
as well as other neuropsychiatric symptoms (NPS) in 
PWD [18–20]. PWD undergo various changes in neuro-
psychological functioning, which adversely impact their 
ability to function independently, their communication, 
and their participation in social activities. This may lead 
to a lack of social engagement and to psychological prob-
lems like anxiety and depression [20, 21]. 
Effective treatment in terms of medication for demen-
tia due to Alzheimer’s disease was first available in the 
early 1990s [22]. However, so far there is no cure for de-
mentia, and, with the increasing prevalence of dementia 
worldwide, the World Health Organisation (WHO) rec-
ognizes dementia as a public health priority [23]. Studies 
show that the effects of pharmacological interventions to 
treat anxiety, depression, or other NPS of dementia are 
modest and, besides, the use of psychotropic medications 
can be associated with major side effects in PWD [24, 25]. 
Therefore, psychosocial interventions should be the first 
step to treat anxiety, depression, and other NPS in PWD 
[26, 27].
Previous studies have investigated the effects of a vari-
ety of psychosocial interventions on anxiety and depres-
sion among PWD [27]. The Sonas program, a multisen-
sory stimulation program developed by Sister Mary 
Threadgold in 1990, is primarily an intervention with the 
aim of promoting the ability of PWD to communicate 
[28]. Several studies have examined the effects of the So-
nas program on communication, cognition, aggression, 
functions of activities of daily living, depression/mood, 
well-being, and quality of life [28]. However, the effects 
on anxiety have only been measured in 1 study; Hutson 
et al. [29] conducted a pilot study with a small number of 
participants (N = 39) and the intervention was short, with 
the Sonas program being applied for up to 7 weeks only. 
The study did not find any significant differences be-
tween the intervention and control groups in terms of 
anxiety. In all, 3 studies have been published that investi-
gated the effects of the Sonas program on depression/
mood, and the findings were ambiguous [29–31]. The 
qualitative study by Dugmore [30] reported positive ef-
fects on the mood of participant as expressed by the staff. 
The study by Jackson et al. [31] found a significant in-
crease in depressive symptoms in the intervention group 
after 8 weeks of the Sonas program and no significant 
changes in the control group. Hutson et al. [29] did not 
report any significant differences between the interven-
tion and control groups in relation to depression. 
As no definite knowledge exists as to whether the So-
nas program does indeed have an effect on anxiety and 
depression in PWD, we wanted to investigate this in NH 
residents with moderate to severe dementia. We further 
wanted to explore whether the effects of this program on 
anxiety and depression could be related to the cognitive 
function of the residents. 
Materials and Methods
Participants and Study Design
In all, 120 residents ≥65 years of age and diagnosed with de-
mentia from 6 NHs in Ireland were included in a randomized con-
trol trial (RCT). The participants were allocated to 1 of 3 groups 
for 24 weeks: (1) a Sonas program group (n = 48), (2) a reading 
group, regarded as an attention placebo group (n = 32), and (3) a 
control group with no intervention (n = 40). The flowchart of study 
participants is shown in Figure 1. The design with 3 groups was 
used to rule out whether the effects of the Sonas program could be 
caused by special attention given to the intervention group, rather 
by the intervention itself [32]. In addition, all participants received 
standard care and attended usual activities in the NH. Recruitment 
of participants, the randomization process, and data collection are 
described in detail elsewhere [33]. Data were collected at baseline 
before randomization (T0), after 12 weeks (T1), and after 24 weeks 
(T2).
Brief Description of the Groups
Sonas Group. The participating NHs had their own Sonas-li-
cenced practitioner (SLP) who attended a 3-day training on how 
to conduct a Sonas session. Each NH had 1 Sonas group consisting 
of 8 participants. The groups were led by SLPs and an assistant. 
The intervention was carried out twice a week for 24 weeks, and 
each session lasted 45 min. The Sonas program followed a fixed 
structure each time and consisted of 11 elements [33]. 
Multisensory stimulation in the Sonas program consists of the 
following elements:
• A signature tune and greeting song
• Exercise to music
• Smell
• A “sing-along” which includes 3 familiar songs
• Relaxation music/massage (the senses of taste and touch are 
stimulated)
• Music with a percussion instrument
• Joining-in proverbs
Anxiety and Depression and the Sonas 
Program
153Dement Geriatr Cogn Disord Extra 2021;11:151–158
DOI: 10.1159/000516804
• Listening to poetry
• A contribution
• A Second “sing-along”
• The closing song and signature tune
Reading Group. The staff at the participating NHs were in-
structed in how to lead and conduct the intervention. The partici-
pants attended the reading group twice a week for 24 weeks, and 
each session lasted for 45 min, while a staff member read from a 
newspaper. 
Control Group. The control group continued with their routine 
activities provided by the NH.
Assessment Scales
Mini-Mental Status Examination
Severity of participants’ cognitive impairment was assessed 
with the Mini-Mental Status Examination (MMSE) screening test 
[34] which has a minimum score of 0 and a maximum score of 30. 
A higher score indicates higher cognitive function [34]. MMSE 
scores of 0–20 are classified as severe to moderate cognitive im-
pairment. The MMSE has been judged to have satisfactory reliabil-
ity as well as construct and criterion validity [35]. 
The Rating Anxiety in Dementia
The Rating Anxiety in Dementia (RAID) scale is a dementia-
specific anxiety scale and consists of 20 items, 18 of which can be 
scored from 0 (absent) to 3 (severe), or U (unable to assess). The 
total score ranges from 0 to 54, with higher scores indicating more 
severe anxiety. Two items (phobias and panic attacks) are assessed 
as present or absent and are not included in the total score [36]. 
The items are rated after interviewing the patient and care staff and 
checking the clinical notes from the previous 2 weeks. A score of 
≥11 suggests significant clinical anxiety [36]. 
The Cornell Scale for Depression in Dementia
The Cornell Scale for Depression in Dementia (CSDD) is an 
observation-based scale that is widely used to assess depressive 
symptoms in PWD [37]. The scale includes 19 items to for assess-
ing a patient’s level of depression based on caregivers’ observations 
over the previous week. The rating scale is from 0 to 38, where 38 
is the highest score, i.e., denoting more severe depression [37]. A 
score of ≥10 on the CSDD suggests significant clinical depression 
in PWD living in NHs [38].
Data Analyses
Demographic and clinical characteristics of participants were 
presented as means and standard deviations (SD) or n (%), as ap-
propriate. Generalized linear mixed models were estimated to as-
sess trends in the proportion of participants with anxiety (RAID 
score ≥11) and depression (CSDD score ≥10). The models con-
tained fixed effects for time point (with baseline as reference), 
group (control as reference), and the interaction between time and 
group. A significant interaction would imply differences between 
groups in trends in the proportion of participants with anxiety or 
depression. Random intercepts for participants nested within NHs 
were included to account for within-patient and within-NH cor-
relations. Random effects for NHs were skipped if no cluster effect 
was present as assessed by intraclass correlation coefficient. The 
results were presented graphically as odds ratios with p values re-
ported in the text. Due to the small group size, the proportions of 
participants with anxiety and depression stratified by level of cog-
nition (MMSE scores of 0–10 vs. 11–20) were presented descrip-
tively and compared by z test for proportions, whenever consid-
ered relevant. All tests were two-sided and p < 0.05 was considered 
statistically significant. The statistical analyses were conducted us-














































Fig. 1. Flowchart of participants.
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Results
There was a total of 120 residents with an average age 
of 85 years from 6 NHs, and 77.5% were female. Partici-
pants had moderate to severe dementia with an average 
MMSE score of 9.0 (SD 7.1); 47.5% had moderate demen-
tia defined as an MMSE score of 11–20 and 52.5% had 
severe dementia (an MMSE score ≤10). Etiological de-
mentia diagnoses were not known. Characteristics of the 
participants at baseline are shown in Table 1. The second-
ary analyses of the study by Strøm et al. [33] examine the 
effects of the Sonas program on anxiety and depression in 
NH residents with moderate to severe dementia. 
Effects on Anxiety
Overall, there were no significant differences (nonsig-
nificant interactions) between the groups regarding the 
trend in the proportion with anxiety. A nonsignificant 
reduction in anxiety from baseline (T0) to 12 weeks (T1) 
was observed in the Sonas group, but no changes were 
found in the reading and control groups (Fig. 2; Table 2).
When stratifying the groups according to MMSE 
score, no changes were found in the occurrence of anxiety 
in any group at any time point (Table 3).
Effects on Depression
There were no overall group differences (nonsignifi-
cant interactions) in the course of depression. Partici-
pants in the Sonas group showed a significant reduction 
in depression from baseline (T0) to 12 weeks (T1) (p = 
0.001) and 24 weeks (T2) (p = 0.009). The increase in de-
pression from T1 to T2 in the reading group was nonsig-
nificant (Fig. 3). The proportions of participants with de-
pression in the 3 groups from baseline to follow-up is 
shown in Table 4. 
When stratifying the groups according to levels of cog-
nition, no significant changes were found in the occur-
rence of depression in any group because there were too 
few cases to be able to calculate p values at any time point 
(Table 5).
Discussion
The overall aim of this study was to examine whether 
the Sonas program had any effect on anxiety and depres-
sion in NH residents with moderate to severe dementia. 









Women, n (%) 93 (77.5) 40 (83.3) 25 (78.1) 28 (70.0)
Men, n (%) 27 (22.5) 8 (16.7) 7 (21.9) 12 (30.0)
Age, years 84.8 (7.0) 86.1 (6.6) 84.9 (7.2) 83.3 (7.1)
MMSE 9.0 (7.1) 7.7 (6.7) 10.0 (7.2) 9.7 (7.5)
RAID sum score 8.7 (6.5)* 9.7 (6.9) 7.4 (5.5)** 8.5 (6.6)
CSDD sum score 8.4 (5.7) 8.8 (4.9) 7.8 (6.0) 8.4 (6.2)
Degree of cognitive function
Moderate (MMSE 11–20) 57 (47.5) 19 (39.6) 17 (53.1) 21 (52.5)
Severe (MMSE 0–10) 63 (52.5) 29 (60.4) 15 (46.9) 19 (47.5)





























Fig. 2. The course of anxiety in the 3 groups (GLIMMIX model).
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To our knowledge, this is the largest RCT, with the lon-
gest follow-up study, to have investigated the effects of the 
Sonas program on anxiety and depression.
Anxiety
The results of this study did not indicate any signifi-
cant reduction in anxiety in any of the groups, and we 
found no overall differences between the groups re-
garding the trend. One reason for the lack of effect 
could be that the study was underpowered, as the aver-
age baseline RAID sum score of the participants was 
<10. This might have limited potentials for a further 
reduction in anxiety, at both the symptom and disease 
level. However, a nonsignificant reduction in anxiety 
from baseline (T0) to the 12-week follow-up (T1) was 
observed in the Sonas group, a finding that should en-
courage a larger-scale study, i.e., including more PWD 
with more severe anxiety. Stratifying the groups ac-
cording to level of cognition (MMSE score), the results 
did not indicate any effect of cognition on anxiety oc-
currence in any of the groups at any time point. Again, 
the main reason was likely due to loss of power. How-
Table 2. The mean RAID sum score (SD) and proportion of participants with anxiety (RAID score ≥11) in the 3 
groups at baseline and at follow-up

















































* The RAID score was missing for 1 participant.
Table 3. The occurrence of anxiety (RAID sum score ≥11) across 
time within the groups stratified by level of cognition (MMSE)
Time point Sonas Reading Control
MMSE score 11–20
T0 (at baseline)
T1 (at 12 weeks)
T2 (at 24 weeks)
MMSE score 0–10
T0 (at baseline)
T1 (at 12 weeks)



















Values express n/N (%). * p = 0.428 (T0 vs. T1), ** p = 0.428 (T0 

































Fig. 3. The course of depression in the 3 groups (GLIMMIX mod-
el).
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ever, we find this analysis worthwhile, as the study by 
Strøm et al. [33] reported that participants with severe 
dementia in the Sonas group experienced significant 
improvements in their communication abilities. 
Depression
Even though we found no overall differences in the 
trend of depressive symptoms between the groups, the 
participants in the Sonas group experienced a significant 
reduction in depression. In the reading group, there was 
a nonsignificant increase in the number of participants 
with depression at the 24-week follow-up. This may indi-
cate that the extra attention the reading group received 
was purposeful. It could be that the Sonas program con-
tributed to the reduction in depression. Stratifying the 
groups according to their cognition level, no significant 
changes in depression were observed in any group at any 
time point. Here again, the reason is likely that too few 
participants with depression were included in each group, 
subdivided on the level of MMSE scores. As for the mean 
RAID sum score, the mean CSDD sum score was also low 
at baseline, indicating that participants had few anxiety 
and depression symptoms.
The study by Hutson et al. [29] reported some im-
provement in anxiety and depressive symptoms in both 
a Sonas and a control group after 7 weeks of interven-
tion. The control group that received treatment as usu-
al showed greater improvement in their anxiety and de-
pressive symptoms than the Sonas group. In contrast, 
the Sonas group had a greater improvement in symp-
toms of behavioral disturbances than the control group 
after 7 weeks. None of the improvements were statisti-
cally significant, but the study may have been under-
powered. 
A study by Jackson et al. [31] found an increase in 
depressive symptoms in the Sonas group after partici-
pating in the Sonas session for a period of 8 weeks. The 
authors could not identify the reason for this but indi-
cated there were qualitative social and psychological 
benefits for the participants. From the perspective of 
NH staff, the Sonas program has some positive effects 
on mood and interactive activities in NH residents with 
dementia [30]. 
Conclusion
Although we observed a within-group effect of the So-
nas program on depression in NH residents with moder-
ate to severe dementia, the results of the our study and 
previous studies are inconclusive with regard to the effects 
on anxiety and depression in NH residents with moderate 
to severe dementia. Participating in the Sonas program 
may have some positive effects on individual levels which 
may not be easy to measure with rating scales. We believe 
that there is a need for larger studies including PWD with 
severe anxiety and depression, to observe the effects of the 
Sonas program on anxiety and depression. 
Statement of Ethics
 Participants’ next-of-kin gave their written informed consent 
since the participants had moderate to severe dementia and were 
unable to sign. The study was approved by the Regional Ethics 
Table 4. The mean CSDD sum score (SD) and proportion of par-
ticipants with depression (CSDD ≥10) in the 3 groups at baseline 
and at follow-up

















































Table 5. The occurrence of depression (CSSD sum score ≥10) over 
time in the 3 groups stratified by level of cognition (MMSE)
Time point Sonas Reading Control
MMSE score 11–20
T0 (at baseline)
T1 (at 12 weeks)
T2 (at 24 weeks)
MMSE score 0–10
T0 (at baseline)
T1 (at 12 weeks)



















Values express n/N (%). There were too few cases to calculate 
p values at any point.
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